Company / FCF Margin
Protara Therapeutics, Inc. FCF Margin History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-340.6%
FY2016
5-year range
-340.6% / -226.1%
FY2014-FY2016
Trend
-50.6%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -281.6% to -340.6% over the past 2 years.
Based on SEC 10-K filings.
-340.6% in FY2016.
Declined from -281.6% to -340.6% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2016, fcf margin decreased 50.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.74 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | -340.6% | -50.6% |
| FY2015 | -226.1% | +19.7% |
| FY2014 | -281.6% | - |
As of FY2016 · SEC 10-K Annual Filings · Last checked Jun 28, 2026